Submit Release

EIN Presswire is celebrating 30 years! Follow us on Substack for customer insights, interviews, and more!

World Media Directory · RSS · Email Newsletters

There were 325 press releases posted in the last 24 hours and 431,622 in the last 365 days.

Merck Press Releases

524 Press Releases

Published on April 5, 2017 - 10:54 GMT

Merck to Present New Data on ZEPATIER® (elbasvir and grazoprevir) and Investigational Combination Therapy MK-3682B for the ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data from the company’s chronic hepatitis C virus (HCV) clinical development programs as well as real-world studies on …

Distribution channels: Companies
Published on April 3, 2017 - 10:48 GMT

Merck to Hold First-Quarter 2017 Sales and Earnings Conference Call on May 2

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2017 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, May 2. …

Distribution channels: Companies
Published on March 31, 2017 - 11:21 GMT

Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA® (...

WILMINGTON, Del. & KENILWORTH, N.J. – Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of …

Distribution channels: Companies
Published on March 24, 2017 - 12:40 GMT

European Medicines Agency’s CHMP Recommends Approval of Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion …

Distribution channels: Companies
Published on March 22, 2017 - 20:12 GMT

Merck Animal Health Completes Acquisition of Vallée S.A.

MADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced it has successfully acquired a controlling interest in Vallée S.A., a leading privately-held producer of animal health …

Distribution channels: Companies
Published on March 14, 2017 - 21:27 GMT

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death …

Distribution channels: Companies
Published on March 14, 2017 - 20:52 GMT

Merck Provides Update on Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Previously Treated ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental Biologics License Application (sBLA) …

Distribution channels: Companies
Published on March 6, 2017 - 13:18 GMT

Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing ...

KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:FE), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review three New Drug …

Distribution channels: Companies
Published on February 28, 2017 - 18:55 GMT

Merck Announces Second-Quarter 2017 Dividend

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.47 per share of the company’s common stock for the second quarter …

Distribution channels: Companies
Published on February 28, 2017 - 18:19 GMT

Recent Survey Finds Many Adults with Diabetes Unaware of Their Increased Risk for Certain Serious Illnesses

KENILWORTH, N.J.--(BUSINESS WIRE)--Many adults with diabetes are unaware of their increased risk for certain serious illnesses, including pneumococcal pneumonia/pneumococcal disease, flu and hepatitis B. This is according to a recent national, online …

Distribution channels: Companies
Published on February 26, 2017 - 17:44 GMT

Merck’s Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE:MRK), known as MSD outside the United States and Canada, today announced results of the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine for the prevention of …

Distribution channels: Companies
Published on February 24, 2017 - 21:23 GMT

In First Phase 3 Trial, Merck’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first Phase 3 study results for V212, the company’s investigational inactivated varicella zoster virus vaccine (VZV) for the …

Distribution channels: Companies
Published on February 16, 2017 - 13:10 GMT

Merck’s Fight Against Infectious Disease Goes Digital with Launch of ILÚM Health Solutions

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of ILÚM Health Solutions, which provides enterprise-wide disease management tools and services to enable improved outcomes …

Distribution channels: Companies
Published on February 14, 2017 - 22:06 GMT

Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer’s Disease to Stop for Lack ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will be stopping protocol 017, also known as the EPOCH study, a Phase 2/3 study evaluating verubecestat, an investigational …

Distribution channels: Companies
Published on February 14, 2017 - 21:29 GMT

Merck’s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection,...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results of a pivotal Phase 3 clinical trial evaluating the safety and efficacy of doravirine (MK-1439), an investigational non- …

Distribution channels: Companies
Published on February 9, 2017 - 14:22 GMT

Merck Foundation Announces Six Program Grant Recipients for Alliance to Advance Patient-Centered Cancer Care

KENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation (Foundation), announced today the selection of the six program sites and National Program Office forming the Alliance to Advance Patient-Centered Cancer Care (the Alliance). With $15 million in …

Distribution channels: Companies
Published on February 3, 2017 - 12:02 GMT

FDA Accepts Two sBLAs for Merck’s KEYTRUDA® (pembrolizumab) for Locally Advanced or Metastatic Urothelial Cancer in Cisplatin-...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental Biologics License Applications (sBLAs) for …

Distribution channels: Companies
Published on February 2, 2017 - 11:46 GMT

Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2016. “The performance of Merck’s broad and balanced portfolio allows us to …

Distribution channels: Companies
Published on January 31, 2017 - 21:06 GMT

European Commission Approves KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the first-line treatment of …

Distribution channels: Companies
Published on January 25, 2017 - 12:06 GMT

Pro Football Hall of Famer and Cancer Survivor Jim Kelly Teams Up with Merck and Leading Cancer Organizations to Launch Your ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Head and neck cancer survivor and Pro Football Hall of Famer Jim Kelly is sharing his personal experience as part of Your Cancer Game Plan, a new awareness campaign focused on helping people with cancer and their loved …

Distribution channels: Companies

Previous 1 2 3 4 5 6 7 8 9 10 11 Next